These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12593654)

  • 1. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
    Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
    J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
    Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
    Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.
    Nöteberg D; Schaal W; Hamelink E; Vrang L; Larhed M
    J Comb Chem; 2003; 5(4):456-64. PubMed ID: 12857114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
    Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
    J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
    Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
    Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
    J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'.
    Romeo S; Dell'Agli M; Parapini S; Rizzi L; Galli G; Mondani M; Sparatore A; Taramelli D; Bosisio E
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2931-4. PubMed ID: 15125962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
    Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
    Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.
    Johansson PO; Chen Y; Belfrage AK; Blackman MJ; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    J Med Chem; 2004 Jun; 47(13):3353-66. PubMed ID: 15189032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.
    Orrling KM; Marzahn MR; Gutiérrez-de-Terán H; Aqvist J; Dunn BM; Larhed M
    Bioorg Med Chem; 2009 Aug; 17(16):5933-49. PubMed ID: 19635672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
    Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
    Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
    J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
    Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
    J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
    Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
    ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
    [No Abstract]   [Full Text] [Related]  

  • 17. New inhibitors of the malaria aspartyl proteases plasmepsin I and II.
    Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2003 Aug; 11(16):3423-37. PubMed ID: 12878137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
    Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
    Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High antiplasmodial activity of novel plasmepsins I and II inhibitors.
    Dell'Agli M; Parapini S; Galli G; Vaiana N; Taramelli D; Sparatore A; Liu P; Dunn BM; Bosisio E; Romeo S
    J Med Chem; 2006 Dec; 49(25):7440-9. PubMed ID: 17149873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.
    Hidaka K; Kimura T; Ruben AJ; Uemura T; Kamiya M; Kiso A; Okamoto T; Tsuchiya Y; Hayashi Y; Freire E; Kiso Y
    Bioorg Med Chem; 2008 Dec; 16(23):10049-60. PubMed ID: 18952439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.